Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine

dc.contributor.authorWyatt, Christina M.
dc.contributor.authorKitch, Douglas
dc.contributor.authorGupta, Samir K.
dc.contributor.authorTierney, Camlin
dc.contributor.authorDaar, Eric S.
dc.contributor.authorSax, Paul E.
dc.contributor.authorHa, Belinda
dc.contributor.authorMelbourne, Kathleen
dc.contributor.authorMcComsey, Grace A.
dc.contributor.authorAIDS Clinical Trials Group Study A5224s Team
dc.contributor.departmentDepartment of Medicine, IU School of Medicineen_US
dc.date.accessioned2016-03-31T16:08:39Z
dc.date.available2016-03-31T16:08:39Z
dc.date.issued2014-09-01
dc.description.abstractBACKGROUND: Antiretroviral therapy (ART) is associated with improved kidney function; however, the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) has been associated with decreased kidney function and proteinuria. METHODS: We examined changes in urine protein:creatinine (UPCR) and urine albumin:creatinine (UACR) ratios in 245 ART-naive participants in A5202 randomized in a substudy to blinded NRTI (abacavir/lamivudine, ABC/3TC, n = 124 or TDF/emtricitabine, TDF/FTC, n = 121) with open-label protease inhibitor (PI) atazanavir/ritonavir or nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. RESULTS: At baseline, 18% of participants had clinically significant proteinuria (UPCR ≥200 mg/g), and 11% had clinically significant albuminuria (UACR ≥30 mg/g). The prevalence of clinically significant proteinuria and albuminuria decreased from baseline to week 96 in all treatment groups. In intention-to-treat analyses, there was a significant effect of NRTI component on fold change in UPCR (P = 0.011) and UACR (P = 0.018) from baseline to week 96, with greater improvements in participants randomized to ABC/3TC. There was no significant effect of NNRTI/PI component on fold change in UPCR (P = 0.23) or UACR (P = 0.88), and no significant interactions between NRTI and NNRTI/PI components. CONCLUSIONS: In this prespecified secondary analysis, ART initiation was associated with improvements in proteinuria and albuminuria, with significantly greater improvements in participants randomized to ABC/3TC versus TDF/FTC. These are the first data from a randomized trial to suggest that initiation of TDF/FTC may not be associated with the same degree of improvement in proteinuria and albuminuria that have been reported with other regimens. Future studies should consider the long-term clinical significance of these findings.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationWyatt, C. M., Kitch, D., Gupta, S. K., Tierney, C., Daar, E. S., Sax, P. E., … McComsey, G. A. (2014). Changes in Proteinuria and Albuminuria with Initiation of Antiretroviral Therapy: Data from a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine versus Abacavir/Lamivudine. Journal of Acquired Immune Deficiency Syndromes (1999), 67(1), 36–44. http://doi.org/10.1097/QAI.0000000000000245en_US
dc.identifier.issn1944-7884en_US
dc.identifier.urihttps://hdl.handle.net/1805/9149
dc.language.isoen_USen_US
dc.publisherOvid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkinsen_US
dc.relation.isversionof10.1097/QAI.0000000000000245en_US
dc.relation.journalJournal of Acquired Immune Deficiency Syndromes (1999)en_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectAlbuminuriaen_US
dc.subjectvirologyen_US
dc.subjectAnti-HIV Agentsen_US
dc.subjectadministration & dosageen_US
dc.subjectHIV Infectionsen_US
dc.subjectdrug therapyen_US
dc.subjectUrineen_US
dc.subjectHIV-1en_US
dc.subjectdrug effectsen_US
dc.subjectProteinuriaen_US
dc.titleChanges in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudineen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms598670.pdf
Size:
202.35 KB
Format:
Adobe Portable Document Format
Description:
Author's manuscript
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: